
Combination Regimens Offer Options in Frontline RCC as Novel Agents Advance Through Pipeline
Clinical trial updates presented during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including from the phase 3 CheckMate 9ER (NCT03141177) and COSMIC-313 (NCT03937219) studies, have further validated …